Incyte Quarterly Income Statement
NASDAQ: INCYHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Incyte revenue and earnings
In the quarter ended Mar 31, 2026, Incyte generated $1.27 billion in revenue, up 20.9% from the same quarter a year earlier. Net income was $303.3 million (+91.7% year over year), for a net margin of 23.8% versus a median of 19.9% in the prior 5 quarters. Gross margin was 91.8% (down from 93.0%) and operating margin 23.7%.
Diluted earnings per share came in at $1.47, up from $0.80.
Summary generated from market data by MetaCap's automated system. Methodology
Incyte income statement (quarterly)
| Quarter (USD) | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 | Q2 20232023-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.27B | 1.51B | 1.37B | 1.22B | 1.05B | 1.18B | 1.14B | 1.04B | 880.89M | 1.01B | 919.02M | 954.61M |
| Revenue growth (YoY) | +20.87% | +27.84% | +20.05% | +16.46% | +19.53% | +16.32% | +23.81% | +9.34% | +8.93% | +9.35% | +11.63% | +4.74% |
| Cost of Revenue | 104.52M | 121.17M | 99.00M | 78.77M | 73.19M | 88.48M | 85.99M | 76.63M | 60.96M | 69.75M | 60.09M | 68.33M |
| Gross Profit | 1.17B | 1.39B | 1.27B | 1.14B | 979.71M | 1.09B | 1.05B | 967.13M | 819.93M | 943.59M | 858.93M | 886.28M |
| Operating Expenses | 867.04M | 1.05B | 823.46M | 606.45M | 774.54M | 788.70M | 905.79M | 1.45B | 728.03M | 756.32M | 644.23M | 692.50M |
| Research & Development | 515.90M | 611.37M | 506.58M | 494.92M | 437.28M | 466.03M | 573.17M | 1.14B | 429.26M | 444.49M | 375.71M | 400.75M |
| Selling, General & Admin | 328.09M | 390.41M | 329.08M | 331.02M | 325.69M | 326.71M | 309.21M | 305.98M | 300.26M | 288.23M | 267.89M | 283.93M |
| Operating Income | 301.12M | 335.86M | 443.52M | 530.31M | 205.17M | 301.51M | 146.09M | -478.13M | 91.90M | 187.27M | 214.71M | 193.78M |
| Interest Expense | 569.00K | 582.00K | 592.00K | 594.00K | 660.00K | 419.00K | 774.00K | 657.00K | 430.00K | 804.00K | 623.00K | 655.00K |
| Other Income (Expense) | 2.77M | 5.66M | 4.04M | 7.31M | 8.10M | 1.61M | 4.93M | 8.29M | -2.03M | -107.98M | 46.37M | 42.67M |
| Pretax Income | 343.60M | 389.94M | 482.31M | 558.01M | 234.19M | 313.72M | 156.52M | -389.78M | 236.16M | 270.96M | 233.80M | 277.60M |
| Income Tax | 40.27M | 90.66M | 58.14M | 153.01M | 75.99M | 112.51M | 50.07M | 54.82M | 66.61M | 69.88M | 62.53M | 74.06M |
| Net Income | 303.33M | 299.28M | 424.17M | 405.00M | 158.20M | 201.21M | 106.46M | -444.60M | 169.55M | 201.08M | 171.27M | 203.55M |
| Net Income growth (YoY) | +91.73% | +48.74% | +298.45% | — | -6.69% | +0.07% | -37.84% | -318.43% | +681.22% | +606.51% | +51.87% | +26.09% |
| EPS (Basic) | 1.52 | 1.51 | 2.17 | 2.09 | 0.82 | 0.89 | 0.55 | -2.04 | 0.76 | 0.90 | 0.76 | 0.91 |
| EPS (Diluted) | 1.47 | 1.46 | 2.11 | 2.04 | 0.80 | 0.90 | 0.54 | -2.04 | 0.75 | 0.89 | 0.76 | 0.90 |
| Shares Outstanding (Basic) | 199.34M | — | 195.67M | 194.00M | 193.71M | — | 192.63M | 218.18M | 224.48M | — | 224.08M | 223.25M |
| Shares Outstanding (Diluted) | 206.83M | — | 201.43M | 198.74M | 198.20M | — | 195.84M | 218.18M | 227.22M | — | 226.17M | 225.65M |
| EBITDA | 324.92M | 359.84M | 467.54M | 553.23M | 227.53M | 324.25M | 168.60M | -456.08M | 113.84M | 209.03M | 236.09M | 214.08M |
| Gross Margin | 91.79% | 91.96% | 92.75% | 93.52% | 93.05% | 92.49% | 92.44% | 92.66% | 93.08% | 93.12% | 93.46% | 92.84% |
| Operating Margin | 23.66% | 22.29% | 32.47% | 43.63% | 19.49% | 25.58% | 12.84% | -45.81% | 10.43% | 18.48% | 23.36% | 20.30% |
| Net Margin | 23.83% | 19.86% | 31.05% | 33.32% | 15.03% | 17.07% | 9.36% | -42.60% | 19.25% | 19.84% | 18.64% | 21.32% |
This table shows 12 quarterly periods of Incyte's income statement, from Q1 2026 back to Q2 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow INCY's reporting calendar. What is a income statement?